Madrigal Pharmaceuticals shares are higher in Tuesday trading (March 31, 2026), with the stock up roughly 4.39% to $527.51. The upside move is consistent with continued risk-on flows into high-growth biotech names tied to the MASH market and follows a recent stretch of positive sell-side commentary and price-target increases.

No single, fresh company-specific headline is broadly circulating for today that cleanly explains the exact timing of the pop. Instead, the rally looks driven by follow-through from recent analyst actions—most notably a late-March price-target increase to $652 from Evercore ISI—plus ongoing bullish framing around Madrigal’s MASH franchise and combination-therapy optionality. These notes have kept investor focus on Rezdiffra as a foundational therapy in MASH and on pipeline additions aimed at expanding Madrigal’s long-term competitive position. (streetinsider.com)

Madrigal’s equity story remains centered on scaling Rezdiffra (resmetirom) after its FDA approval and defending the franchise with lifecycle strategies, including patents and potential combinations. Recent coverage has also emphasized Madrigal’s in-licensing of Pfizer’s DGAT2 inhibitor ervogastat and plans to run a drug–drug interaction study in 2026 ahead of broader combination discussions, which has helped sustain a higher valuation framework even during day-to-day volatility. (investing.com)

Traders will be watching for any incremental commercialization metrics (prescriptions, payer coverage breadth, and adherence signals) that can confirm the pace of Rezdiffra uptake, as well as concrete timelines for Madrigal’s combination strategy (including the ervogastat interaction study). With the stock already trading near and above some published 12-month targets referenced in recent market commentary, additional upside may hinge on new data points, guidance updates, or clearer read-throughs on competitive dynamics in MASH. (kr.tradingview.com)